UK medical diagnostics specialist Circassia has reached the milestone of completing 40 million tests worldwide with its NIOX VERO, a small medical device to detect asthma.
The company’s NIOX technology measures airway inflammation, a key indicator of asthma, by testing the amount of exhaled nitric oxide (FeNO) in a patient’s breath. In one test, that can be taken during a GP check-up or at the asthma clinic, doctors and their patients can instantly see what is happening in the airway and tailor treatments to provide the most appropriate care.
With 340 million people affected by asthma globally, Circassia is keen to keep spreading the word about FeNO testing and help healthcare professionals and patients diagnose and manage asthma.
Recognising the company’s achievements, the Global Health & Pharma Awards recently named Circassia Global Leaders in FeNO Testing 2021.
The judges said: “Having already performed over 40 million FeNO tests, it’s clear to see NIOX has been invaluable in helping physicians across the world see airway inflammation clearly. Whilst serving a truly global clientele, the firm remains committed to innovation and delivering outstanding support to ensure every asthma patient receives the best possible care.”
Circassia COO Jonathan Emms said: “This accolade recognises our efforts in innovating and serving the global asthma community. We are honoured to have such dedicated teams working on NIOX VERO and the faith of the medical community who are offering the device to such vast numbers of patients. The 40 million tests mark was a true milestone for us. We are reaching more than 5,400 patients a day but there are 340 million more reasons to keep testing and we will strive to make sure we continue to help physicians offer asthma patients the best care they can.”
